About this source
- Kind
- Regulatory or official document
- Population
- Not applicable (regulatory record); underlying trial population per the pivotal Phase 3 trials
- Primary or secondary
- primary
- Peer review
- unknown
- Retraction status
- None known
- Date checked
- 14 August 2026
Limitations
US regulatory document, usable for context/comparison only; not a UK regulatory source and must not be presented as if it establishes any UK status.
Cited in
Vyleesi label adverse events
PT-141 (Bremelanotide) · Safety finding
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.